Emerging evidence suggests that genetic alterations leading to MAPK/ERK pathway dysregulation (e.g., RAS, BRAF) facilitate complex interactions between tumor cells, the tumor microenvironment, and the immune system (69). The gene discussed is BRAF; the disease is neoplasm.